TOP TEN perturbations for 40095_at (Homo sapiens)

Organism: Homo sapiens
Gene: 40095_at
Selected probe(set): 209301_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 40095_at (209301_at) across 6674 perturbations tested by GENEVESTIGATOR:

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-9.455921
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).

RAF1 overexpr. study 1 (retrovirus) / control virus infected MCF7 cell sample

Relative Expression (log2-ratio):-8.292179
Number of Samples:2 / 2
Experimental RAF1 overexpr. study 1 (retrovirus)
MCF-7 cell line stably transfected with retrovirus containing cDNA for RAF1. The following retroviral construct was used: pLNCRaf-1 contains human Raf-1 cDNA encoding an amino terminally truncated form of Raf-1 that is constitutively active, which is inserted into retroviral vector pLNCX encoding neomycin resistance gene (NeoR). MCF7 cells were maintained in EMEM supplemented with 10% FBS and 20ug/ml insulin.
Control control virus infected MCF7 cell sample
MCF7 cell line transfected with pZipneo retrovirus, which is an empty retroviral vector encoding neomycine resistance gene (NeoR). MCF7 cells were maintained in EMEM supplemented with 10% FBS and 20ug/ml insulin.

colorectal cancer study 1 / normal colon tissue

Relative Expression (log2-ratio):-7.9226046
Number of Samples:6 / 6
Experimental colorectal cancer study 1
Laser microdissected human colorectal cancer sample.
Control normal colon tissue
Laser microdissected human colonic epithelial cells sample.

colorectal adenoma study 7 (colonic mucosa) / adjacent colon mucosa sample

Relative Expression (log2-ratio):-7.5095882
Number of Samples:5 / 5
Experimental colorectal adenoma study 7 (colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal adenoma.
Control adjacent colon mucosa sample
Adjacent colon mucosa sample obtained by laser capture microdissection (LCM) from patients with colorectal cancer.

colorectal adenoma study 7 (colonic mucosa) / normal colon mucosa sample

Relative Expression (log2-ratio):-7.375904
Number of Samples:5 / 5
Experimental colorectal adenoma study 7 (colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal adenoma.
Control normal colon mucosa sample
Histopathological normal colon mucosa sample obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)

Relative Expression (log2-ratio):-7.2010603
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).

colorectal cancer study 33 (carcinoma; colonic mucosa) / adjacent colon mucosa sample

Relative Expression (log2-ratio):-7.1848536
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control adjacent colon mucosa sample
Adjacent colon mucosa sample obtained by laser capture microdissection (LCM) from patients with colorectal cancer.

Langerhans cell histiocytosis study 1 / normal plasmocytoid dendritic cell sample

Relative Expression (log2-ratio):7.0797834
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal plasmocytoid dendritic cell sample
Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population.

colorectal cancer study 33 (carcinoma; colonic mucosa) / normal colon mucosa sample

Relative Expression (log2-ratio):-7.0511694
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control normal colon mucosa sample
Histopathological normal colon mucosa sample obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.

colorectal cancer study 33 (carcinoma; colonic crypt) / adjacent colonic crypt epithelial cell sample

Relative Expression (log2-ratio):-6.932724
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic crypt)
Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control adjacent colonic crypt epithelial cell sample
Adjacent colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from patients with colorectal cancer.